PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma

Simon Puttick; Christopher Bell; Nicholas Dowson; Stephen Rose; Michael Fay

doi:10.1016/j.drudis.2014.10.016

PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma

Drug Discov Today. 2015 Mar;20(3):306-17. doi: 10.1016/j.drudis.2014.10.016. Epub 2014 Nov 6.

Authors

Simon Puttick¹, Christopher Bell², Nicholas Dowson³, Stephen Rose³, Michael Fay⁴

Affiliations

¹ Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia.
² CSIRO - The Australian e-Health Research Centre, Level 5, UQ Health Science Building, RBWH, Herston, QLD 4029, Australia; School of Medicine, The University of Queensland, 288 Herston Road, Herston, QLD 4006, Australia.
³ CSIRO - The Australian e-Health Research Centre, Level 5, UQ Health Science Building, RBWH, Herston, QLD 4029, Australia.
⁴ School of Medicine, The University of Queensland, 288 Herston Road, Herston, QLD 4006, Australia; Genesis Cancer Care, Lake Macquarie Private Hospital, 36 Pacific Highway, Gateshead, NSW 2290, Australia; Royal Brisbane and Women's Hospital, Butterfield Street, Herston, QLD 4006, Australia. Electronic address: mike.fay@cancer.com.au.

PMID: 25448762
DOI: 10.1016/j.drudis.2014.10.016

Abstract

Glioma is the most aggressive brain tumour, resulting in death often within 1-2 years. Current treatment strategies involve surgical resection followed by chemoradiation therapy. Despite continuing improvements in the delivery of adjuvant therapies, there has not been a dramatic increase in survival for glioma. Molecular imaging techniques have become central in the development of new therapeutic strategies in recent years. The multimodal imaging technology of positron emission tomography/magnetic resonance imaging (PET/MRI) has recently been realised on a preclinical scale and the effect of this technology is starting to be observed in preclinical drug development for glioma. Here, we propose that PET/MRI will play an integral part in the development of new diagnostic and therapeutic strategies for glioma.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Brain Neoplasms* / diagnosis
Brain Neoplasms* / diagnostic imaging
Brain Neoplasms* / therapy
Glioma* / diagnosis
Glioma* / diagnostic imaging
Glioma* / therapy
Humans
Magnetic Resonance Imaging*
Positron-Emission Tomography*